8-K: AEON Biopharma Secures $5.99M in Private Placement

AEON Biopharma announced a private placement of common stock and warrants, alongside a convertible note exchange with Daewoong, to raise capital and restructure debt.

Summary

• AEON Biopharma, Inc. entered into a Securities Purchase Agreement on November 12, 2025, for a private placement with certain investors.
• The private placement involves the issuance and sale of Class A common stock, pre-funded warrants, warrants, and true-up warrants.
• The purchase price for shares is $0.9116 per share, and for pre-funded warrants is $0.9115 per warrant.
• The first closing, expected the week of November 17, 2025, will involve 1,964,905 shares (or pre-funded warrants) for a total of $1,791,010.92.
• The second closing, subject to stockholder approval and the Daewoong exchange, will involve 4,616,924 shares (or pre-funded warrants) and 6,581,829 warrants, totaling $4,208,326.24.
• Total expected proceeds from the private placement are approximately $5,999,337.16.
• Warrants issued in the private placement will be exercisable at $1.09392 per share (120% of the share price) for five years from the second closing, with full ratchet anti-dilution protection (not below $0.30387).
• Pre-funded warrants have an exercise price of $0.0001 per share and no expiration date.
• True-up warrants will be issued to investors after the second closing and Daewoong exchange to maintain their post-exchange investment percentage, exercisable at $0.0001 per share with no expiration.
• The company also entered a binding term sheet with Daewoong Pharmaceutical Co., Ltd. on November 12, 2025, to exchange existing senior secured convertible notes (totaling $15 million principal from March and April 2024).
• The Daewoong exchange will result in a new $1.5 million senior secured convertible note due April 12, 2030, approximately 23,103,694 shares of common stock or pre-funded warrants, and 8,000,000 Daewoong warrants.
• Daewoong warrants will have the same terms as the private placement warrants, exercisable at $1.09392 per share for five years.
• A registration rights agreement requires the company to file a registration statement for the resale of these securities within 20 days of the earlier of the second closing or termination of the Securities Purchase Agreement after the first closing.
• The company will use the net proceeds for working capital and general corporate purposes.
• A beneficial ownership limitation of 9.99% (adjustable up to 19.99% with 61 days notice) applies to the exercise of warrants.
• The company acknowledges that the issuance of these securities may result in substantial dilution to existing common stock holders.

Sentiment

Score: 6

Explanation: The filing indicates a successful capital raise and debt restructuring, which are positive for the company's financial stability and operational runway. However, the significant dilution to existing shareholders and the contingent nature of the second closing and Daewoong exchange introduce elements of risk and uncertainty, balancing the overall sentiment to moderately positive.

Positives

• Secured approximately $5.99 million in new capital through a private placement, improving liquidity and funding general corporate purposes.
• Restructured $15 million in existing senior secured convertible notes held by Daewoong, converting a significant portion into equity and extending the maturity of a remaining $1.5 million note to 2030.
• Warrants issued to investors have an exercise price 20% above the share purchase price, indicating a potential future upside for the company if the stock price increases.
• Investors receive participation rights in future unregistered financings, potentially providing a stable source of future capital.
• The company will file a registration statement to allow for the resale of the newly issued securities, providing liquidity for investors.

Negatives

• The issuance of a significant number of shares and warrants will result in substantial dilution to existing shareholders.
• The second closing of the private placement and the Daewoong exchange are contingent on stockholder approval, introducing uncertainty and potential delays.
• The full ratchet anti-dilution protection on the warrants could lead to further dilution if the stock price drops significantly, though it is capped at $0.30387.
• Liquidated damages of 1.0% per month (up to 10.0% total) are payable to investors if the company fails to meet registration statement filing and effectiveness deadlines, adding financial risk.
• The company's obligations under the transaction agreements are absolute and unconditional, regardless of the dilutive effect on other shareholders.

Risks

• Inability to close the proposed Private Placement or Exchange due to failure to obtain stockholder approval.
• Failure to satisfy other customary closing conditions for the Private Placement or Exchange.
• Potential dilution of outstanding shares of Common Stock from the issuance of new securities, which may be substantial.
• The company's obligations under the Transaction Agreements are unconditional and absolute, irrespective of any dilutive effect.
• The SEC may take the position that the offering of some or all of the Registrable Securities is not eligible for delayed or continuous offering under Rule 415, or may require investors to be named as underwriters.
• The company's ability to maintain its listing on the NYSE American, as compliance with listing requirements is ongoing.
• Risks and uncertainties detailed in the company's Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company anticipates using the net proceeds from the private placement for working capital and general corporate purposes. The consummation of the second closing and the Daewoong exchange are subject to obtaining stockholder approval and satisfying other customary closing conditions. The company is committed to maintaining its NYSE American listing and will file a registration statement for the resale of the newly issued securities.

Management Comments

• The company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions.
• The company further acknowledges that its obligations under the Transaction Agreements, including, without limitation, its obligation to issue the shares underlying the Securities pursuant to the Transaction Agreements, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the company may have against any investor and regardless of the dilutive effect that such issuance may have on the ownership of the other stockholders of the company.

Industry Context

This financing and debt restructuring activity is common for biopharmaceutical companies, especially those in development stages, to secure necessary capital for ongoing operations and clinical programs. The terms, including warrants and anti-dilution provisions, reflect typical structures used to attract investors in the biotech sector, often balancing immediate capital needs with future equity considerations. The exchange of convertible notes with a strategic partner like Daewoong also indicates ongoing collaboration and financial management within the industry.

Comparison to Industry Standards

• The warrant exercise price at 120% of the share purchase price is a common incentive for investors in private placements, offering upside potential while providing a premium to the company.
• Full ratchet anti-dilution protection for warrants, while beneficial to investors, is a strong protection that can be more dilutive to existing shareholders compared to narrower anti-dilution clauses. The floor price of $0.30387 provides some limit to this dilution.
• The beneficial ownership limitation of 9.99% (with an option to increase to 19.99%) is a standard provision in private placements to prevent any single investor from immediately gaining too much control without further regulatory scrutiny or shareholder approval.
• The liquidated damages for registration statement delays are a common feature in private placement agreements, incentivizing the company to provide liquidity for investors' unregistered shares in a timely manner, aligning with market expectations for such transactions.

Related Party Transactions

• The company entered into a binding term sheet with Daewoong Pharmaceutical Co., Ltd. for the exchange of outstanding senior secured convertible notes. Daewoong is a significant existing noteholder and will receive new securities as part of this transaction.

Stakeholder Impact

• Shareholders: Will experience significant dilution due to the issuance of new shares and warrants in the private placement and the Daewoong exchange. Their approval is required for the second closing and the Daewoong exchange.
• Investors (in private placement): Will acquire common stock, pre-funded warrants, and warrants at a specified price, with anti-dilution protection and registration rights, providing them with potential upside and liquidity.
• Daewoong Pharmaceutical Co., Ltd.: Will convert existing debt into a mix of a new convertible note, equity, and warrants, restructuring their investment and potentially strengthening their strategic alignment with AEON Biopharma.
• Creditors: The restructuring of Daewoong's convertible notes impacts the company's debt profile, potentially improving its balance sheet and ability to meet obligations.

Next Steps

• First Closing of the Private Placement is expected to occur the week of November 17, 2025.
• The company will seek stockholder approval for the Second Closing of the Private Placement and the Daewoong Exchange.
• The company and Daewoong expect to enter into a definitive exchange agreement at a later date.
• The company will prepare and file a proxy statement with the SEC for the stockholder meeting to obtain the Requisite Stockholder Approval.
• The company will file a registration statement with the SEC covering the resale of the newly issued securities no later than 20 days following the earlier of the Second Closing or the termination of the Securities Purchase Agreement after the First Closing and prior to the Second Closing.
• The company will use the net proceeds from the private placement for working capital and general corporate purposes.

Key Dates

Recommendation

The capital raise and debt restructuring provide necessary funding and improve the company's financial structure, which are positive developments. However, the significant dilution from the new share issuances and the contingent nature of key parts of the transaction (stockholder approval) introduce considerable uncertainty. Investors should hold to monitor the successful completion of these transactions and assess the impact of dilution on per-share value before making further investment decisions.

Keywords

Private Placement, Convertible Note Exchange, Warrants, Pre-Funded Warrants, Equity Financing, Debt Restructuring, Dilution, SEC Filing, AEON Biopharma, Daewoong Pharmaceutical, NYSE American